Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satavaptan Cirrhotic Ascites Treatment Study
2006-000132-27Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ascites and Cirrhosis comparing Satavaptan 5–10 mg daily + conventional treatment with Placebo + conventional treatment (2 arms). Primary endpoint: Proportion of patients with ascites worsening at 12 weeks. Started Mar 2006; status: completed.
02
Drugs
satavaptan
03
Conditions
ascitesCirrhosis
Beyond the preview
Go deeper on 2006-000132-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000132-27.